Company / Return on Assets (ROA)
4D Molecular Therapeutics, Inc. Return on Assets (ROA) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-28.4%
FY2025
5-year range
-31.6% / -16.0%
FY2021-FY2025
Trend
-57.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) has fluctuated over the past 6 years, ranging from -31.6% in FY2023 to -16.0% in FY2021.
Based on SEC 10-K filings.
-28.4% in FY2025 with a 5-year CAGR of -11.3%.
Improved from -31.6% to -28.4% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -1.2pp
- 5-Year Change
- -11.3pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 57.8% year-over-year.
- Peak return on assets (roa) was recorded in FY2021.
- Lowest return on assets (roa) in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -28.4% | -57.8% |
| FY2024 | -18.0% | +43.1% |
| FY2023 | -31.6% | -16.1% |
| FY2022 | -27.2% | -69.8% |
| FY2021 | -16.0% | +6.2% |
| FY2020 | -17.1% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026